Medisys PLC (MDY) Providing innovative solutions to the rapidly growing point-of-care diagnostic and healthcare worker safety markets. For more than 35 years, companies in the Medisys group have been advancing healthcare through development, manufacture and distribution of revolutionary medical products. The Group's mission is to become a leading worldwide provider of diagnostic systems and medical safety products enabling rapid, cost effective, on-site delivery of healthcare solutions.
For more than three decades, Medisys' primary operating unit, Hypoguard, has been devoted to advancing personal and professional healthcare management. The Company's core focus is diabetes glucose self-monitoring - a rapidly growing market of nearly $5 billion worldwide.
'Medisys-group.com'
'Hypoguard.com'

15/02/2006
Medisys reported a 'considerable improvement' in trading during the first four months of its financial year, and said the business has been cash-flow neutral for the year to date.
The medical products company said competition in its core long-term care blood glucose monitoring business has not intensified. A drop in sales amid intense competition in the market caused a fall in sales and profits last year.
Sales volumes have recovered to previous highs by cutting prices and offering various promotions, Medisys reported this morning.
Margin improvements have been achieved faster than originally anticipated, it added. The company has benefited from cost saving measures implemented in the second half of the last financial year and cost reductions for its proprietary biosensor products.
Meanwhile, it has completed the development and manufacturing scale up of the first of the new systems it has designed for Menarini, the fifth largest worldwide branded marketer of blood glucose monitoring systems.
While the launch date is not yet clear, (Around March 1) Medisys predicted that sales of the products will be one of its key revenue growth drivers in the current financial year.


LATEST ON MDY V'S ROCHE COURT CASE
MDY V'S ROCHE COURT CASE Case IS Dismissed. http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread
My apologies for any one that was on MDY it looks like we have been stitched up like a kipper the sale of Hypoguard blood glucose monitoring business at that price looks like an sp of 3p against the close of 6.4p what can I say no one could have seen this coming a total sell out and that is what I have done.

Driver Hi,

I know a lot of people got burnt by MDY, especially after the safety syringe failure/fiasco, and the last interims stated that the blood glucose monitoring was not producing the results expected, due to the very 'competetive' market for MDY products.

The lastest deal may make a difference, but IMVHO it is a long way off, as Menarini may have a deal, but they haven't shown they can sell MDY products into a competetive market yet.

Cheers,
PM



Medisys PLC
23 June 2005



Embargoed until 0700 23 June 2005

Medisys PLC
('Medisys' or 'the Company')

Unaudited Interim Results for the Six Months Ended 31 March 2005

Financial Highlights

Turnover decreased by 16% to 14.2 million (2004: 16.8 million) including
0.9 million impact of the weakening in US Dollar/Sterling exchange rate
Gross margin, before exceptional items decreased to 24% (2004: 40%)
Administration costs before exceptional items reduced by 18% to 2.1 million
as cost reductions take effect;
Operating loss before exceptional items and amortisation 2.5 million
(2004: 0.3 million);
Loss before tax 3.3 million (2004: 1.1 million)
Loss per share before exceptional items 0.69p (2004: 0.41p)
Exceptional items of 6.8 million reflecting write-off of Futura Safety
Syringe assets

Business Highlights

Favourable judgement in relation to Roche Method Patent litigation as
announced earlier this week; litigation relating to infringement of other
patent continues;
Intensified competition in the Company's core Long Term Care ('LTC') market
results in decreased sales and reduced gross margins;
Sales of products into LTC were 6.5 million in the period (2004: 9.1
million at a constant exchange rate);
Sales of Advance Micro-draw, principally to Liberty Medical were 2.9
million (2004: 1.0 million) ;
New production equipment now commissioned and improved gross margin on
Advance Micro-draw anticipated towards the end of the financial year;
New supply agreement with Stada Arzneimittel A.G. for supply of Advance
MicroDraw in German market;
Agreement with major pan-European marketing partner close to signature;
Cost cutting initiatives expected to reduce overheads in 2006 by 2m

David Wong, Chairman commented: 'The first half of the year has been difficult
as the previously reported increased competitive pressure in the LTC market
segment persisted. The Company is responding to the competition by selectively
reducing prices and by developing special promotional programmes for certain
customers. We are already beginning to see some new business being generated by
these activities. Despite these actions it is clear that it will take some time
for this situation to improve and continuing poor financial performance is
anticipated for the remainder of the financial year.

I am pleased at the positive development announced earlier this week on the
Roche litigation. While it is difficult to quantify the precise impact, I
believe that the market perception of the litigation has adversely affected our
competitive position. The reduced threat should add a positive impetus to our
recovery in the LTC segment.

'Today's announcement of a new supply agreement with Stada Arzneimittel in
Germany is a further important step in the expansion of our international
business. Also in Europe we are at the final stages of agreeing a formal
contract with a major pan-European marketing partner and we are confident that
this will be finalised and signed shortly. We anticipate that these
developments, together with our cost reduction initiatives, will help restore
the Company's financial performance to more acceptable levels in the next
financial year.'


Enquiries:

Medisys PLC (23/06/05) 020 7067 0700
Michael Barry, Chief Financial Officer (Thereafter) 01394 387333

Weber Shandwick Square Mile 020 7067 0700
Kevin Smith/John Moriarty


Embargoed until 0700 23 June 2005


http://www.uk-wire.com/cgi-bin/articles/200506230700369348N.html

=======================================================

Medisys PLC
14 July 2005



For Immediate Release 14 July 2005


Medisys PLC
('Medisys' or 'the Company')

Medisys Announces Major Strategic Alliance With Menarini Diagnostics

Medisys announces that its Hypoguard subsidiary has entered into a marketing and
distribution agreement (the 'Agreement') with A. Menarini Industrie
Farmaceutiche Riunite S.r.l. ('Menarini Group').

Under the Agreement, Hypoguard will provide the Diagnostic Division ('Menarini
Diagnostics') of Menarini Group with a panel of blood glucose monitoring
systems, based on the project 'Ferrara', that has been exclusively engineered
for Menarini Diagnostics. The new systems will offer market-leading features
including micro blood sample size and quick read-time together with an
attractive ergonomically designed full-featured meter. The Ferrara project,
which is based on the Company's proven Advance Micro-draw system, represents
another step forward in terms of the Company's proprietary biosensor technology
and is in the final stages of production scale-up. The recently completed
manufacturing capacity upgrade at Hypoguard's Minneapolis facility is sufficient
to accommodate the volumes anticipated under the Agreement. The Menarini glucose
monitoring systems developed according to the Ferrara project will be marketed
under Menarini Diagnostics brand name(s).


http://www.uk-wire.com/cgi-bin/articles/200507140706208676O.html

pm1
The pic and links are working OK my end, this we be interesting, we will have a race in percentage terms against MDY and your MPM and see how we get on.

Driver Hi,

It will be interesting to watch both I think.

I saw the news on MDY when the Menarini RNS came out, so having held them about 2 years ago, I thought about maybe buying some. I tried a dummy buy and sell on IWeb, and I could buy loads, but I couldn't sell any, probably because the MM's have so many to get rid of first, so I didn't bother.

I bought the two MPM trades on Friday, 350,000 @ 1.375 plus the 31910 @ 1.43, and with the brokers note giving a DCF of 6.24p, a rise to 4p or 5p is quite possible, in the short term.

What do you think MDY will rise to in the short term ?

Cheers,
PM

pm1
How short, 10p by xmas.

Driver Hi,

OK, thanks :)

I notice sequestor is not stalking you everywhere, posting personal attacks on you, and attacks on your stocks, he is deranged, and reported to abuse.

See my MPM BB, and you will see why.

Cheers,
PM

Lets try keeping on topic !

Nearly finished back where we started possible blue tomorrow.

seq
Why do you consider this new thread MDY as a ramp, it is just a new thread like any other. You are becoming a bit of a pain, please remove or edit your post.

calm down driver its` not likely to alter the share price or the angle of the worlds axis,I haven`t even mentioned you as a ramper.
enjoy the rise.

seq
Your sense of humour is a bit much some times, point taken.

rejoice driver rejoice,as Maggi said ,

did you see the late Ted Heath on tele last night he was asked at the time she was removed if it was true that when the news of the sacking was telephoned, he said "rejoice, rejoice", a pause for effect then he replied:-

" not true i said ` rejoice, rejoice,rejoice`"

seq
Ted Heath father of the house, just like me. I am rejoiceing at this sp are you getting on board.

spread`s a bit sharp just now drive- hope you bgt. a while back

g`luck

oops sorry just looked at the chart- hope you bgt. at the low might be kinder-lol

seq
No bought this week at 4p. Ramp coming 10p+ by xmas

Very nice 11.5% rise today, well on track for recovery.

Two steps forward one step back, topped up today on the dip.

Recovered well towards close.

Nice little tick up today.

July 14, 2005 - Hypoguard Announces Major Strategic Alliance With Menarini Diagnostics


Hypoguard ("Hypoguard" or "the Company")

Hypoguard announces that it has entered into a marketing and distribution agreement (the "Agreement") with A. Menarini Industrie Farmaceutiche Riunite S.r.l. ("Menarini Group"). Under the Agreement, Hypoguard will provide the Diagnostic Division ("Menarini Diagnostics") of Menarini Group with a full family of blood glucose monitoring systems, based on the project Ferrara', that has been exclusively engineered for Menarini Diagnostics. The new systems will offer market-leading features including small blood sample size and quick read-time, together with an attractive, ergonomically designed full-featured meter. The Ferrara project, which is based on the Hypoguard's Advance Micro-draw system, represents another step forward in terms of the Company's proprietary biosensor technology and is in the final stages of production scale-up. The recently completed manufacturing capacity upgrade at Hypoguard's Minneapolis facility is sufficient to accommodate the volumes anticipated under the Agreement. The Menarini glucose monitoring systems will be marketed under Menarini Diagnostics brand name(s).

Hypoguard has granted Menarini Group rights to sell the new systems world-wide, with the exception of the USA, Canada and Mexico. Menarini Diagnostic is finalizing its launch plans, but is anticipated to introduce the systems in its key European territories within approximately six months. The Agreement provides for an initial term of eight years with a mechanism for the term to be extended. In keeping with the long-term nature of the alliance, the Agreement also provides for other Hypoguard products (such as next generation systems and products customized for specific market niches) to be made available exclusively to Menarini Diagnostics for distribution as and when they are developed.

Menarini Group, with Headquarters in Florence, Italy, is a research-based pharmaceutical company with annual revenues exceeding 1.9 billion Euros and 12,000 employees throughout the world. Menarini Diagnostics has a well established blood glucose monitoring business throughout Europe and certain other international territories. Menarini Diagnostics employs approximately 750 people.

David Wong, Chairman of Hypoguard's parent company, Medisys PLC, commented: "We are delighted to become a long-term strategic partner of Menarini's diagnostics division, which is a leading player across Europe. Menarini is a highly respected and long established medical products company and we believe that this alliance will enable Hypoguard to rapidly expand the presence of its products in the European market."

Crescenzio Izzo, General Manager of Menarini Diagnostics commented:
"The strategic partnership with Hypoguard will provide us a strong basis for our continued growth in blood glucose monitoring, making full profit of Hypoguard's capacity for product innovation coupled with our strengths in marketing."

- Ends -

Contact:
Hypoguard 800-818-8877
Jonathan Chapman